14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ALNY ranks #17512 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Alnylam Pharmaceuticals Stock Forecast NASDAQ:ALNY

$138.62 (-0.41%)

Volume: 475k

Closed: Jan 19, 2022

Hollow Logo Score: -5.692

Alnylam Pharmaceuticals Stock Forecast

$138.62 (-0.41%)

Volume: 475k

Closed: Jan 19, 2022

Score Hollow Logo -5.692

Alnylam Pharmaceuticals Company Profile

300 Third Street

Cambridge MA 02142



Industry: Biotechnology

Sector: Healthcare

Alnylam Pharmaceuticals


Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin amyloidosis (ATTR); ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR for the treatment of various forms of ATTR amyloidosis; Fitusiran, an investigational RNAi therapeutic that is in Phase I clinical trial for the treatment of hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-AS1 for the treatment of hepatic porphyrias. Its product development programs also include ALN-AAT for the treatment of alpha-1 antitrypsin deficiency-associated liver disease; ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia; ALN-HBV for the treatment of Hepatitis B virus; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Ionis Pharmaceuticals, Inc.; Novartis Pharma AG; Novartis/Arrowhead; F. Hoffmann-La Roche Ltd; Roche/Arrowhead; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; Ascletis BioScience Co., Ltd.; Monsanto Company; Sanofi Genzyme; The Medicines Company; Arbutus Biopharma Corporation; Protiva Biotherapeutics, Inc.; The University of British Columbia; and Acuitas Therapeutics Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE